Astronauts take pharmaceutical interventions to mitigate bone density loss.

the verdict

SUPPORTED

the evidence backs this

Recorded sources

3 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that astronauts take pharmaceutical interventions to mitigate bone density loss?

Yes. Multiple studies and reviews confirm that space travelers and astronauts utilize or evaluate pharmaceutical interventions, such as bisphosphonates and antiresorptive drugs, to mitigate the skeletal demineralization caused by microgravity.

Verdict: SUPPORTED · 3 sources for, 0 against · Last checked 5 Aug 2026

The analysis

The claim is specific, empirical, and well-supported by multiple peer-reviewed papers in the retrieved set (e.g., papers 1, 2, and 4) which explicitly discuss the use and development of pharmacological countermeasures against spaceflight-induced bone density loss. There are no papers refuting the claim. Thus, the verdict is SUPPORTED.

Evidence for · 3

The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.

2021

Discusses proposed and utilized pharmacological interventions, including antiresorptive and anabolic drugs, to mitigate microgravity-induced bone loss in space travelers.

Get citation

S, G., M, M., & L, M. (2021). The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.. doi.org. https://doi.org/10.3390/ijms22094585

See more details

More for · 2

2022

Reviews treatment options such as bisphosphonates and RANKL antibodies that decrease bone resorption and promote bone formation during spaceflight.

Get citation

R, B., M, W., H, S., M, H., M, I., & D, G. (2022). Microgravity-Related Changes in Bone Density and Treatment Options: A Systematic Review.. doi.org. https://doi.org/10.3390/ijms23158650

Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight

2023

Evaluates the potential use of denosumab and other pharmaceutical options as countermeasures against microgravity-induced osteopenia and bone demineralization.

Get citation

Rengel, A., Tran, V., & Toh, L. S. (2023). Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight. doi.org. https://doi.org/10.3357/amhp.6053.2023

Related receipts

Is it true that Ozempic causes bone loss? CONTESTED related question, same topic
Is it true that astronauts can live in microgravity for over a year, though they lose bone density and muscle mass? PARTIAL LEAN related question, same topic
Is it true that smoking reduces bone mineral density? PARTIAL LEAN related question, same topic
Is it true that people grow shorter as they age due to spinal disc compression and bone density loss? SUPPORTED related question, same topic

Receipt History

first checked05 Aug 2026

judged → SUPPORTED · 8505 Aug 2026

Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.

Check your own claim

Challenge the receipt

I have a source that contradicts this verdict I have a source that supports it No source: request a receipt review Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work